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RESEARCH ARTICLE

Defining phenotypic and functional
heterogeneity of glioblastoma stem cells
by mass cytometry
Luciano Galdieri,1 Arijita Jash,1 Olga Malkova,2 Diane D. Mao,3 Patrick DeSouza,1 Yunli E. Chu,4
Amber Salter,5 Jian L. Campian,1,6 Kristen M. Naegle,4 Cameron W. Brennan,7 Hiroaki Wakimoto,8
Stephen T. Oh,2,6 Albert H. Kim,3,6 and Milan G. Chheda1,6,9
Department of Medicine, 2Center for Human Immunology and Immunotherapy Programs, and 3Department of
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Neurosurgery, Washington University School of Medicine, St. Louis, Missouri, USA. 4Biomedical Engineering and Center
for Biological Systems Engineering, Washington University in St. Louis, St. Louis, Missouri, USA. 5Division of Biostatistics,
Washington University School of Medicine, St. Louis, Missouri, USA. 6Siteman Cancer Center, Washington University in
St. Louis, St. Louis, Missouri, USA. 7Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New
York, USA. 8Brain Tumor Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA. 9Department of
Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.

Most patients with glioblastoma (GBM) die within 2 years. A major therapeutic goal is to target
GBM stem cells (GSCs), a subpopulation of cells that contribute to treatment resistance and
recurrence. Since their discovery in 2003, GSCs have been isolated using single-surface markers,
such as CD15, CD44, CD133, and α6 integrin. It remains unknown how these single-surface marker–
defined GSC populations compare with each other in terms of signaling and function and whether
expression of different combinations of these markers is associated with different functional
capacity. Using mass cytometry and fresh operating room specimens, we found 15 distinct
GSC subpopulations in patients, and they differed in their MEK/ERK, WNT, and AKT pathway
activation status. Once in culture, some subpopulations were lost and previously undetectable
ones materialized. GSCs that highly expressed all 4 surface markers had the greatest self-renewal
capacity, WNT inhibitor sensitivity, and in vivo tumorigenicity. This work highlights the potential
signaling and phenotypic diversity of GSCs. Larger patient sample sizes and antibody panels are
required to confirm these findings.
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Introduction
Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Standard therapy includes
surgery, radiation, temozolomide chemotherapy, and, more recently, tumor-treating fields (1). Recurrence, on average, occurs 6 months after maximal therapy (2). GBM stem cells (GSCs), also known as
tumor-propagating cells or tumor-initiating cells (3), may be one reason for inevitable recurrence, as they
are highly resistant to radiation and chemotherapy (4–6). GSCs were first isolated using an antibody against
the cell-surface protein CD133 (Prominin-1) (7). CD133hi cells have clonogenic self-renewal capacity and
efficiently engraft and form intracranial tumors in immunocompromised mice (8, 9). Although sorting by
CD133 enriches for GSC function, CD133lo cells can also exhibit clonogenic self-renewal and asymmetric
cell division, albeit less efficiently (10, 11). Alternative single-surface markers such as CD15 (SSEA-1),
CD44, α6 integrin, and A2B5 may also enrich for the GSC state (12–16). The literature has used the term
GSC with varying definitions. We use it here as synonymous with a stem cell marker–bearing GBM cell.
GSCs tend to be enriched in serum-free media conditions, often referred to as stem cell media conditions. It remains unknown how GSC populations defined by single-surface markers compare with each
other, in terms of intracellular signaling and function and whether expression of different combinations
of these markers is associated with differences in the probability of tumor-forming capacity. More broadly,
it remains unknown whether all GSCs are alike or have their own hierarchy of function. These issues are
important for how we study GBM in vitro and in animal models and understand intratumor and intertumor heterogeneity and treatment resistance.
1
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Mass cytometry is a quantitative analytical technique whereby single cells labeled with antibodies
tagged with rare earth metals are ionized and analyzed by time-of-flight mass spectrometry. This largely
overcomes the spectral overlap typical of standard flow cytometry, which limits the number of observations
possible on a given cell. As such, mass cytometry theoretically enables the use of up to 100 analysis channels, with over 50 currently available heavy metal isotopes to study (17, 18).
We used mass cytometry to evaluate the intracellular states associated with 4 commonly used GSC
surface markers, CD15, CD44, CD133, and α6 integrin. We measured normal neural stem cell–associated
intracellular markers that have also been implicated in GSC proliferation, migration, and tumorigenesis,
e.g., Sox2 (19–21), Musashi (22–24), Nanog (25), and Nestin (26) (7, 8, 12). We also probed core developmental pathways that are often activated in GSCs and for which targeted therapies are available, such
as PI3K/AKT (27), MEK/ERK (28), JAK/STAT (29), WNT/β-catenin (30, 31), NF-κB (32, 33), and
MAPK/P38 (34); their downstream effectors; and cancer-associated markers (Table 1).
To study GBM by mass cytometry, patient samples were quickly dissociated into single cells and fixed
prior to analysis to avoid loss of phenotypic markers and cell populations (35, 36). We herein report that
GSC subpopulations differ in signaling, self-renewal potential, and in vivo tumorigenicity depending on
which surface markers are used to isolate them. We also report that the composition of the overall GSC
population shifts in culture, compared with fresh isolates.

Results
Mass cytometric analysis of fresh patient samples identified a heterogeneous distribution of GSC subpopulations
between patients. We obtained fresh tumor samples from the operating room of 6 patients at the time of
GBM diagnosis (Table 2). We dissociated tumors into single-cell suspension within 30 minutes after
tissue acquisition. We obtained an average of 1.35 × 104 live cells per mg of tissue, and 3 × 106 viable cells were immediately labeled for mass cytometry. To identify GSC subpopulations based on stem
cell–surface marker state, using 4 GSC markers and their combinations, we considered 15 theoretical
states, assuming each cell can have high or low expression of each marker, and 1 non-GSC state (low
expression for all 4 surface markers). For positive and negative controls for cell-surface and intracellular
GSC markers, we used the patient-derived GSC line 0308 cultured in Neurobasal media supplemented
with growth factors and cultured in DMEM media containing 10% FBS for 6 weeks, respectively. GSCs
grown in the presence of FBS are phenotypically distinct from cells grown in serum-free media (37),
and FBS-containing media reduced the expression of all 4 surface markers (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.128456DS1).
From the 6 patient specimens, we identified all 16 possible states (Figure 1). The entire population of
GSCs, as defined as high expression of at least one GSC cell-surface marker, comprised an average of
29.6% (range from 22.2% to 37%) of live cells analyzed. We observed a heterogeneous distribution of
GSC subpopulations between patients. The range of high expression for each individual marker was
3.3%–9.3% CD15, 3.1%–53% CD44, 6.6%–19% CD133, and 2.0%–16.2% α6 integrin. Some populations
were rare and represented less than 1% of the entire GSC population, e.g., CD15hiCD44hiCD133hi and
CD15hiCD44hiCD133hiα6 integrinhi (Figure 1 and Supplemental Table 1).
We also assessed the expression of the intracellular neural stem cell–associated proteins Sox2,
Musashi-1, Nestin, and Nanog. We observed that all 4 intracellular markers were expressed in GSCs and
non-GSCs (Figure 2). We also found that 14%–50% of the cells expressing any of the 4 neural stem cell–
associated intracellular markers also expressed a single GSC cell-surface marker (Figure 2). Conversely,
compared with non-GSCs, not all GSC subpopulations had high levels of expression of one of these neural
stem cell–associated intracellular markers (Supplemental Figure 2).
Compared with non-GSCs, fresh GSC subpopulations differed in MEK/ERK, WNT, and AKT pathway activation and had increased WNT and NF-κB activation. To determine the activation level of intracellular pathways,
we used mass cytometry with a panel of 20 antibodies (Table 1). Activation of the PI3K/AKT, MEK/
ERK, JAK/STAT, NF-κB, and MAPK/P38 pathways was determined by increased phosphorylation of
AKT (pAKT), ERK (pERK), STAT3 (pSTAT3), P65 (pP65), and P38 (pP38), respectively. Activation of
the WNT pathway was determined by increased expression of non–phospho-β-catenin. We found that the
quadruple-high subpopulation, CD15hiCD44hiCD133hiα6 integrinhi, had high expression of pERK and non–
phospho-β-catenin compared with cells with low expression of surface markers (Figure 3A). In addition,
the subpopulation CD44hiCD133hiα6 integrinhi also had consistently high expression of phospho-ERK and
JCI Insight 2021;6(4):e128456 https://doi.org/10.1172/jci.insight.128456
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Table 1. Antibodies used in mass cytometry analysis
Antigen

Conjugate

Clone

Catalog no.

Supplier

CD15
CD44
CD133
α6 Integrin
Non–phospho-β-catenin
pAKT [S473]
pS6 [S235/S236]
pERK1/2 [T202/Y204]
p-P38 [T180/Y182]
pStat3 [Y705]
pNF-κB p65 [S529]
p4E-BP1 [T37/T46]
SOX2
Nanog
Musashi-1
Nestin
p53
MYC
p21
Ki-67
CD45A

144Nd
166Er
170Er
164Dy
165Ho
152Sm
172Yb
171Yb
156Gd
158Gd
160Gd
149Sm
150Nd
169Tm
155Gd
146Nd
143Nd
176Yb
159Tb
168Er
089Y

W6D3
BJ18
293C3
G0H3
D13A1
D9E
N7-548
D13.14.4E
D3F9
4/P-Stat3
REA348
236B4
O30-678
N31-355
14H1
196908
DO-7
9E10
12D1
Ki-67
HI30

3164001B
3166001B
130-090-851
3164006B
3165027A
3152005A
3172008A
3171010A
3156002A
3158005A
130-095-212
3149005A
3150019B
3169014A
3155013B
3146015
3150024A
3176012B
3159026A
3168001B
3089003B

Fluidigm
Fluidigm
Miltenyi
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Miltenyi
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm
Fluidigm

Used only in samples from patients 5 and 6.

A

non–phospho-β-catenin among all 6 patients. In contrast, CD15hi and CD15hiCD133hi subpopulations had
consistently low expression of pAKT (Figure 3A).
GSCs as a group had significantly greater WNT activation (P < 0.01 patients 1–4 and 6) compared with
cells lacking expression of all of the GSC surface markers (quadruple low; Figure 3B). We also tested whether the presence of greater numbers of stem cell–surface markers is associated with greater WNT activation.
Combining our patient data and collapsing the subpopulations into single, double, triple, or quadruple-high
states from each patient sample, and correcting for multiple hypothesis testing, we found that increased
numbers of surface markers were associated with increased expression of non–phospho-β-catenin (Figure
3C; P values in Supplemental Table 2), a transcription factor that is activated when a Wnt ligand binds to
the Frizzled and LRP6 coreceptors (38). The quadruple-high subpopulation, CD15hi CD44hi CD133hi α6
integrinhi, had the highest protein expression of non–phospho-β-catenin in samples from patients 1, 2, 3, 5,
and 6. In patient 4, which lacked the quadruple-high subpopulation, the subpopulations with high expression of any 3 surface markers had the greatest abundance of non–phospho-β-catenin. Additionally, GSCs
as a group had increased expression of pP65 compared with non-GSCs, a surrogate of NF-κB pathway
activation (33) (Figure 3B; P < 0.01 patients 1–4 and 6). Myeloid cells in the tumor microenvironment did
not likely skew our interpretation (Supplemental Figure 3).
Short term culture was associated with both loss and gain of GSC subpopulations. We were only able to derive
one GSC line from our 6 patient specimens (patient 4, GSC line B142). We test whether GSC subpopulation
compositions were perturbed by culture conditions. Using FACS (Supplemental Figure 4), we observed that
although the initial specimen contained 14 GSC states, after short-term culture (14 passages), only 10 subpopulations were detected (Figure 4A). Interestingly, although we failed to detect 5 GSC subpopulations that
had existed in the fresh sample, 2 subpopulations were detectable in the cultured sample (Figure 4, A and B).
GSC subpopulations in short-term and long-term culture had different self-renewal capacities, depending on the
cell-surface markers used to define them. Using B142, we measured the relative rates of clonogenic self-renewal
of each sorted GSC population using the extreme limiting dilution assay (ELDA) (39, 40). Clonogenic
potential ranged from 0.4% to 6.3% (Figure 4C). The cells expressing high levels of CD44 and CD133 only
(CD44hiCD133hi) and all 4 markers (CD15hiCD44hiCD133hiα6 integrinhi) had the greatest degree of self-renewal capacity, with clonogenic potential of 6.3% and 4.9%, respectively (Figure 4C; CD44hi, P < 0.01;
JCI Insight 2021;6(4):e128456 https://doi.org/10.1172/jci.insight.128456
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Table 2. Patient information
Survival time (days)

Presentation

Tumor location

Patient 1

Patient 2

Patient 3

Patient 4

Patient 5

317

728

527

182

109 (alive)

Patient 6

131 (alive)
77-year-old right49-year-old man
handed woman
31-year-old right67-year-old rightwho presented
82-year-old right60-year-old leftwho presented
handed man who
handed woman who with headaches, handed woman who
handed man who
with subtle wordpresented with 1
presented with a
presented with focal dizziness, and
presented with
finding difficulties,
month of headaches
seizure
concentration
partial seizures
headaches
acalculia, and
and blurry vision
problems
agraphia for 3 weeks
Left medial
Left posterior
temporal and into
Left temporal
Right temporal
Left temporal
Right parietal
frontal
corpus callosum
MGMT promoter
MGMT promoter
MGMT promoter
MGMT promoter
MGMT promoter
MGMT promoter
methylated; other
not methylated
not methylated
methylated
not methylated
methylation
genetics unknown
indeterminate
CDKN2A/B loss
CDKN2A/B loss
CDKN2A/B loss CDK4 amplification CDK4 amplification
TERT promoter
TERT promoter
TERT promoter
TERT promoter
TERT promoter
mutation
mutation
mutation
mutation
mutation

MET amplification EGFR amplification, EGFR amplification, EGFR amplification, EGR amplification
EGFR vIII mutant EGFR vIII mutant
with duplication
of exons encoding
kinase domain
Tumor genetics
PTEN loss of
CREBBP truncation
PTEN loss of
MDM4 amplification
function
intron 13
function
NF1 loss of function
MLL3 spice site MDM2 amplification
PIK3C2B
mutation
amplification
NOTCH1 V1575L
SPTA1 mutation FRS2 amplification EGFR mutation
subclonal mutation
del intron 13–1, del
intron 1–7
Equivocal CDK6 and
HGF amplifications
QKI truncation in
exon6
No EGFR, IDH1,
No IDH1, PDGFRA No IDH1, PDGFRA No IDH1, PDGFRA No IDH1, PDGFRA No IDH1 mutation
Pertinent negatives
PDGFRA mutations
mutations
mutations
mutations
mutations
by IHC
Microsatellite status
Stable
Stable
Stable
Stable
Stable
Unknown
Tumor mutational
Low
Low
Low
Low
Low (3 mut/MB)
Unknown
burden

CD133hi, P < 0.01; α6 integrinhi, P = 0.0179; CD44hiα6 integrinhi, P < 0.01; CD133hiα6 integrinhi, P = 0.0194;
CD15hiCD44hiα6 integrinhi, P < 0.01; CD44hiCD133hiα6 integrinhi, P = 0.0417).
Similarly, we identified from 3 patient-derived GSC lines in long-term culture (Table 3) 13 of the 16
possible states (Supplemental Figure 5). Clonogenic potential as measured by ELDA ranged from 0.3%
to 12.3% in TS667 GSCs (Figure 5A); 0.3% to 46.3% in 0308 GSCs (Figure 5B); and 1.4 % to 9.7% in
MGG8 GSCs (Figure 5C). For TS667 and 0308, the quadruple-high subpopulation had the greatest
degree of in vitro self-renewal capacity (Figure 5, A and B) (TS667, CD15hi, P < 0.01; CD44hi, P <
0.01; CD15hiCD133hi, P = 0.0437; CD15hiα6 integrinhi, P = 0.0104; CD44hiα6 integrinhi, P < 0.01; 0308,
CD15hiα6 integrinhi, P < 0.01; CD44hiα6 integrinhi, P < 0.01; CD133hiα6 integrinhi, P < 0.01; CD15hiCD44hiα6 integrinhi, P < 0.01; CD15hiCD133hiα6 integrinhi, P < 0.01). For MGG8, both the α6 integrin
high and the quadruple-high subpopulations had the greatest extent of clonogenic potential (Figure 5C)
(CD15hi, P < 0.01; CD44hi, P < 0.01; CD133hi, P < 0.01; CD15hiα6 integrinhi, P < 0.01; CD44hiCD133hi,
P < 0.01; CD133hiα6 integrinhi, P < 0.01; CD15hiCD44hiCD133hi, P < 0.01; CD15hiCD44hiα6 integrinhi, P
< 0.01; CD15hiCD133hiα6 integrinhi, P < 0.01; CD44hiCD133hiα6 integrinhi, P < 0.01).
GSC subpopulations differed in intracellular pathway activation states and downstream effectors in vitro, depending on the cell-surface markers used to define them. For mass cytometry studies of GSC subpopulations, we used
JCI Insight 2021;6(4):e128456 https://doi.org/10.1172/jci.insight.128456
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Figure 1. All GSC subpopulations exist in patients. Pie charts demonstrate the percentage of each GSC subpopulation relative to the total number of cells
analyzed from each patient sample. The percentage of cells that highly express at least one of CD15, CD44, CD133, or α6 integrin is indicated under the
patient number. GSC, glioblastoma stem cell.

antibodies against the same 4 cell-surface markers above. We also assessed signal activation using antibodies against pAKT, pERK, pSTAT3, non–phospho-β-catenin, pP65 (NF-κB), and pP38. In TS667 GSCs, the
quadruple-high subpopulation, CD15hiCD44hiCD133hiα6integrinhi, had the greatest average activation of
all 6 pathways studied (Figure 6A). In particular, similar to the fresh operating room GSC specimens, this
subpopulation of TS667 had the highest abundance of pERK and non–phospho-β-catenin compared with
other GSC subpopulations (Figure 6A). In 0308 GSCs, the CD44hiCD133hi subpopulation presented the
strongest activation of the PI3K/AKT, WNT/β-catenin, NF-kB, and MAPK/P38 pathways (Figure 6B).
In MGG8 GSCs, the CD15hiCD44hiα6 integrinhi subpopulation had the strongest activation of the PI3K/
AKT, WNT/β-catenin, and NF-kB pathways (Figure 6C).
To determine whether GSC subpopulations may differ in cell biological processes, we assayed
markers of cell proliferation (Ki-67) (41–43) and RNA translation (p4E-BP1, pS6) (44, 45). In TS667
GSCs, expression of Ki-67, pS6 and p4E-BP1 were the highest in the quadruple-high subpopulation
JCI Insight 2021;6(4):e128456 https://doi.org/10.1172/jci.insight.128456
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Figure 2. Intracellular neural stem cell–associated proteins are expressed in GSCs and non-GSCs. For each indicated intracellular protein, all cells that
highly express it total to 100%. The subpopulation contribution to this total is indicated. GSCs, glioblastoma stem cells.

(Figure 7A). In 0308 GSCs, the CD44hiCD133hi subpopulation had high expression of Ki-67, pS6,
and p4E-BP1 (Figure 7B). In MGG8 GSCs, the triple-high, CD15hiCD44hiα6 integrin hi, and the quadruple-high, CD15hiCD44hiCD133hiα6 integrinhi, subpopulations had greatest expression of Ki-67, pS6,
and p4E-BP1 (Figure 7C). In summary, in standard culture conditions, high expression of a single-cell
surface marker was inadequate to identify the state with greatest self-renewal capacity or greatest intracellular pathways activation.
Given that we observe heterogenous activation of WNT signaling in patient samples and cell lines,
we next investigate whether GSC subpopulations have differential sensitivity to WNT inhibition. We
treated cells with the canonical WNT inhibitor XAV939, which increases degradation of β-catenin and
decreases β-catenin–mediated transcription (46). We found that the quadruple-high cells were more sensitive to WNT inhibition than α6 integrinhi cells in TS667 (CD15hi, CD44hi, and CD133hi, nonsignificant;
JCI Insight 2021;6(4):e128456 https://doi.org/10.1172/jci.insight.128456
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Figure 3. GSC subpopulations have differential activation of MEK/ERK, WNT, AKT, and NF-κB pathways. (A) Side panels indicate the expression level
(high, black; low, gray) of the cell-surface markers that define each subpopulation. Across each patient, the indicated protein in each subpopulation is
shown; heatmaps indicate fold protein expression relative to non-GSCs. Six intracellular pathways (pAKT, pERK, pSTAT3, non–phospho-β-catenin, pP65,
and pP38) and three intracellular downstream effectors (Ki-67, p4E-BP1, and pS6) were examined. (B) Expression of non–phospho-β-catenin and pP65 in
GSCs and non-GSCs, on log scale. Kruskal-Wallis with Mann-Whitney U post hoc tests were used, *P < 0.05 vs. non-GSCs. (C) Expression of non–phospho-β-catenin in GSCs grouped by the number of highly expressed surface markers, on log scale. Kruskal-Wallis with Bonferroni’s post hoc tests were
used; *P < 0.05. GSC, glioblastoma stem cell.

α6 integrinhi, P = 0.042), CD15hi, CD44hi, and CD133hi cells in 0308 (CD15hi, CD44hi, and CD133hi, P
< 0.01; α6 integrinhi, nonsignificant). We found no significant sensitivity to WNT inhibition in MGG8
GSC subpopulations (Figure 8).
GSC subpopulations differed in their in vivo tumorigenicity. We used a murine intracranial implantation assay
to examine whether distinct GSC-associated cell-surface marker profiles are associated with differences in
in vivo tumorigenesis. Using the MGG8 patient GSC line, we used magnetic beads and FACS to enrich
and isolate subpopulations based on single-surface markers or high expression of all 4 markers, and compared them with unsorted cells grown in standard GSC-enriching media conditions. Upon implantation
into the right frontal lobes of NCG female immunodeficient mice (NOD-Prkdcem26Cd52Il2rgem26Cd22/NjuCrl), we
followed mice for survival. The quadruple-high subpopulation had the shortest median survival (20.5 days)
compared with unsorted (median beyond 100 days, P < 0.01). The cells expressing single markers were also
JCI Insight 2021;6(4):e128456 https://doi.org/10.1172/jci.insight.128456
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Figure 4. GSC populations are lost and gained in culture, and CD15hiCD44hiCD133hi α6 integrinhi (quadruple high) cells
and CD44hiCD133hi cells derived from patient 4 are the most clonogenic. (A) B142 GSCs were derived from patient
4. Black indicates the presence of the indicated GSC subpopulation; hash pattern indicates its absence. (B) Pie chart
indicates the percentage of each GSC subpopulation relative to the total B142 population. (C) Clonogenic self-renewal
for B142 cell line was assessed by extreme limiting dilution analysis (24, 5, and 1 cells per well; 12–18 replicates per
dilution). The experiment was repeated 3 times, and the results are shown as mean ± SEM. ANOVA with Tukey’s post
hoc tests were used to assess the significance of differences between each GSC subpopulation. *P < 0.05 vs. quadruple-high. GSC, glioblastoma stem cell.

more aggressive than the unsorted cells: α6 integrin (29.5 days, P < 0.01), CD15 (33.5 days, P < 0.01), CD133
(43 days, P < 0.01), or CD44 (53 days, P = 0.0802) (Figure 9). Mice implanted with CD133hi (P = 0.0183) or
CD44hi (P = 0.0209) cells had significantly longer survival than quadruple high as well. Together, these data
suggest that even when cells are grown in stem cell–promoting media conditions, upon implantation these
unsorted cells had different growth dynamics in vivo than surface marker–enriched cells. Additionally, there
may be important in vivo differences between quadruple-high cells and specific subpopulations.

Discussion

The CD15hiCD44hiCD133hi α6 integrinhi subpopulation was enriched for GSC characteristics. We used mass cytometry to characterize the single-cell protein signaling status of fresh GSCs. This may prove a valuable addition to single-cell RNA sequencing in understanding GBM biology and heterogeneity. Single-cell RNA
sequencing can detect rare GSC populations cells and transcriptional activation of pathways (47); however,
it does not render a clear observation of proteomic intracellular signaling. A multiomic approach can better
clarify GBM biology and heterogeneity.
Because GSCs may be one reason for inevitable recurrence in GBM, single-cell analysis of protein states in heterogeneous GSCs may lead to GSC subpopulation–specific therapies. Bulk proteomic
JCI Insight 2021;6(4):e128456 https://doi.org/10.1172/jci.insight.128456
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Table 3. Patient characterization for TS667, 0308, and MGG8 cell lines
GSC line (ref.)

A

Patient

TS667 (78)

69-year-old man

0308 (37)

37-year-old man

MGG8 (79)

WomanA

Description

High levels amplification of PDGFRA
Amplification of EGFR
Amplification of MET
Amplification of CDK6
Loss of PTEN
Loss of CDKN2A
Homozygous deletion of INK4a/ARF locus (chromosome 9)
Loss of chromosome 10q
Trisomy of chromosomes 7 and 20
Partial trisomy of chromosome 19
Translocation t(10;21)
Local amplification of EGFR (approximately 6 copies of EGFR/cell)
PTEN mutation (nonsense mutation at amino acid 76)
P53 mutation (M237V, point mutation in DNA binding domain)
Amplification of MYCN
Amplification of PDGFRA
Amplification of MDM2
Homozygous deletion of CDKN2A/B

Further details of this patient are restricted by the institutional requirements.

analysis using mass spectrometry with patient-derived GSCs can identify differential expression of proteins and phosphoproteins. Recent mass spectrometry studies found increased protein phosphorylation, including the histone methyltransferase enhancer of zeste homolog 2 and the cell motility protein
hyaluronan-mediated motility receptor in GSCs compared with neural stem cells from the adult human
brain (48); TGF-β receptor type 2 in GSCs grown with EGF compared with GSCs grown in the presence of serum (49); and activation of S6K pathways in GBM cells compared with non-GSCs (50). Proteomics studies also associated the single amino acid variants S1559T in phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1 and V632A in dynein axonemal assembly factor 5 with
increased risk of GBM (51). However, these studies were done in bulk cells and did not allow single-cell
resolution to identify GSC subpopulations and analyze their proteome. In its ability to enable single-cell
analysis of the signaling status of proteins, mass cytometry adds granular context to bulk transcriptional and proteomic analysis.
Individual or double positive expression of cell-surface markers has been widely studied (9, 14, 16, 52),
but multidimensional stem cell–surface marker studies in GBM are rare and have only been performed
in vitro (53). By using 4 stem cell–surface markers, we found 15 states of GSCs exist, each with different
levels of activation of core signaling pathways in both patient samples and cell lines. We found that the
quadruple-high subpopulation, CD15hiCD44hiCD133hiα6 integrinhi, had the highest capacity for clonogenic
self-renewal in 2 of 4 GSC lines in culture (Figures 4 and 5). α6 integrin hi and CD44hiCD133hi also had high
clonogenic capacity, but other subpopulations did not follow a clear pattern of surface marker combination
and clonogenic potential.
The quadruple-high cells exhibited the highest activation of MEK and WNT pathways among GSC
subpopulations in patient samples 1, 2, and 3 and patient samples 1, 2, 3, 5, and 6, respectively, and in the
long-term cultured TS667 GSCs. To put this in context, it is known that GSC sphere formation requires
ERK activation (28), and GSC tumorigenic capacity and self-renewal requires both the WNT activation
and the crosstalk between MEK/ERK and PI3K/AKT (28, 54). EGFR is commonly amplified or mutated in GBM (28) and MEK/ERK and PI3K/AKT are downstream of EGF signaling (55). Activation of
MEK/ERK and PI3K pathways suppresses apoptosis (56) and cellular differentiation (28) while promoting
cellular proliferation (57). In addition, depletion of the Wnt secretion protein Evi/Gpr177 in both glioma
and GSCs decreases cell proliferation and apoptosis (54). Taken together, increased MEK/ERK and WNT
activation in the quadruple-high subpopulation suggests that inhibiting these pathways may be clinically
useful in targeting this highly clonogenic subset of glioma cells.
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Figure 5. GSC subpopulations vary in their self-renewal potential. Frequency of clonogenic cells was assessed by extreme limiting dilution analysis using
GSC subpopulations derived from (A) TS667, (B) 0308, and (C) MGG8 lines (120, 60, 24, 5, and 1 cells per well; 12–18 replicates per dilution). The experiment
was repeated 3 times, and results are shown as mean ± SEM. ANOVA with Tukey’s post hoc tests were used to assess the significance of differences
between each GSC subpopulation; *P < 0.05 vs. quadruple-high. GSC, glioblastoma stem cell.

In vivo, the quadruple-high GSCs were the most aggressive, along with the α6 integrinhi. Our results
do not support a clear linear relationship between number of surface markers present and tumorigenicity.
For example, CD15hiα6 integrinhi was not particularly more clonogenic than CD15hiCD133hiα6 integrinhi
or CD15hi was not more clonogenic than CD15hiCD133hi. GSCs may represent a plastic state that can be
adopted by cancer cells in response to environmental cues rather than a clonal entity defined by stable
surface markers expression and distinct phenotypes (58, 59). It is important to consider the possible
JCI Insight 2021;6(4):e128456 https://doi.org/10.1172/jci.insight.128456
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Figure 6. Mass cytometry detects core signaling within single cells among 13 GSC subpopulations from 3 patient-derived lines in long-term culture.
Violin plots indicate protein levels for 6 intracellular pathways (pAKT, pERK, pSTAT3, non–phospho-β-catenin, pP65, and pP38) in (A) TS667, (B) 0308,
and (C) MGG8 cells. Bottom panels show the levels (high, black; low, gray) of the cell-surface markers defining each subpopulation. Arrows highlight the
subpopulation with the highest average protein abundance, as discussed in the text. GSC, glioblastoma stem cell.

effects of media conditions, secreted factors, and the tumor microenvironment on this plasticity. Another
point worth noting is that our experimental design did not put “unsorted” cells through the process of
flow cytometry, and we cannot rule out that the intervention of flow cytometry did not enhance in vivo
tumorigenicity of sorted cells.
From the 6 pathways studied, WNT/β-catenin and NF-κB were the main pathways associated with GSC identity. All GSC subpopulations from fresh tumor samples had more activation of WNT/β-catenin signaling
(indicated by non–phospho-β-catenin) than non-GSC components of the tumor, suggesting that activation
of this pathway may be a distinct feature of GSCs. β-Catenin–mediated transcriptional activity is required
JCI Insight 2021;6(4):e128456 https://doi.org/10.1172/jci.insight.128456
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Figure 7. GSC subpopulations with increased activation of PI3K/AKT, WNT/β-catenin, NF-κB, and MAPK/P38 core
signaling pathways have increased expression of markers for cell proliferation and translation. Violin plots indicate
protein status of markers of cell proliferation (Ki-67) and translation (p4E-BP1, pS6) by GSC subpopulation in (A) TS667,
(B) 0308, and (C) MGG8 cells. Bottom panels show the levels (high, black; low, gray) of the cell-surface markers defining
each subpopulation. Arrows highlight the subpopulation with the highest average protein expression, as discussed in
the text. GSC, glioblastoma stem cell.

for self-renewal frequency through interaction with the transcription factor TCF7L2 and disruption of this
interaction reduces tumor volume of subcutaneous GSC xenografts (60). Among GSCs, the quadruple
high, CD15hiCD44hiCD133hiα6 integrinhi cells, had the greatest activation (Figure 3A), which may explain
their increased self-renewal capacity in vitro and increased in vivo tumorigenic capacity. These data corroborate that in previous work that demonstrated that accumulation of active non–phospho-β-catenin due
to WNT stimulation contributes to differentiation arrest and maintenance of the self-renewal capacity in
mouse neural stem cells and malignant glioma patient samples (31). Recent findings suggest that instead of
a subpopulation hierarchy, GSCs are capable of transiting between GSC states (58). Although there might
not be a unipotent and irreversible subpopulation, the increased clonogenicity together with increased in
vitro and ex vivo WNT activation in the quadruple-high GSC suggest that the degree of plasticity might be
associated with WNT signaling and tumorigenic potential.
In vivo limiting dilution tumor formation assays have demonstrated that CD133-positive tumor
cells are highly tumorigenic in brains of immunocompromised mice, whereas CD133-negative cells seldom form detectable tumors (7, 61). However, our work and previous results (10–15) suggest that not all
CD133-containing populations have increased clonogenicity. In fact, our work, although not testing in
vivo limiting dilutions, suggests that quadruple-high GSCs had the highest clonogenic renewal. This is
consistent with the finding that decreased activation of WNT/β-catenin pathway inhibits proliferation
and GBM sphere formation (62).
Our findings also reveal NF-κB activation in GSCs in vivo. We observed increased phosphorylation of
the NF-κB subunit, P65, in GSCs from all 6 patients, compared with cells devoid of the 4 surface markers.
NF-κB is activated in many human tumors, including glioma (63). In GSCs, the phosphorylation of P65
is increased due to overexpression of the A20 protein (TNFAIP3), a mediator of the NF-κB pathway and
cell survival (64), and GSCs in culture have increased phosphorylation and nuclear localization of P65,
with resultant increased expression of NF-κB–regulated genes (65) and associated therapeutic resistance
(33). Inhibition of P65 phosphorylation in combination with TMZ increases GBM cell apoptosis in vitro
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Figure 8. Quadruple-high GSCs are sensitive to WNT inhibition. TS667, 0308, and MGG8 GSC subpopulations were
incubated for 5 days with the canonical WNT pathway inhibitor XAV939 and cell viability was measured. The experiment
was repeated 3 times, and results are shown as means ± SEM. GSCs, glioblastoma stem cells.

compared with TMZ alone (66). The increased P65 phosphorylation we found in GSCs suggests that
NF-κB can be used as a potential target to increase TMZ sensitivity of the treatment-resistant GSCs.
We expected to find increased activation of PI3K/AKT, MEK/ERK, JAK/STAT, and MAPK/P38
pathways in cell with increased clonogenic potential. However, we found no distinguishable difference
in expression of pAKT, pERK, pSTAT3, and pP38 between the GSC subpopulations among the fresh
patient specimens we studied. Our expectations were based on studies using longer term cultures of GSCs
in which AKT drives renewal in GSCs in vitro (67). Similarly, JAK/Stat pathway activation is required
for in vitro proliferation and self-renewal of patient-derived GSCs (68), whereas Stat3 inhibition decreases
expression of neural stem cell transcription factor, Olig2, and inhibits neurosphere formation in GSCs (68).
We also expected patient GSCs would have P38 inactivation because inhibition of P38 signaling maintains
stemness of patient-derived CD133-positive cells (34). Instead, most GSC subpopulations from patients
2, 3, and 6 showed increased phosphorylated P38. The absence of differences in these pathways in fresh
patient specimens was at odds with what we observed in our 2 long-term cultures. Larger numbers of fresh
specimens will add more clarity to these observations; however, these findings may highlight the differences
between cells in situ and in culture.
Intracellular neural stem cell–associated proteins were expressed in GSC and non-GSC cells. Sox2, Musashi-1,
Nestin, and Nanog have been considered intracellular markers of the GSC state because of their high
expression in neurosphere cultures and previous reports that they are required for maintenance of GSC
identity (8, 20, 25, 69). In contrast, we found that the 4 intracellular markers were expressed in cells with
and without surface markers associated with the GSC state (Figure 2). Additionally, compared with their
quadruple-negative counterparts, not all GSC subpopulations had high levels of expression of all stem
cell–associated intracellular markers (Supplemental Figure 2), suggesting that high levels of these intracellular markers are not necessarily linked to the surface marker–defined GSC state in vivo and regulate
genes expression and signaling involved in GBM malignancy in both non-GSCs and GSCs (70). Together,
although our study includes a small number of patient samples, it does not support the one-to-one correspondence of high intracellular expression of neural stem cell proteins with cell-surface expression of GSC
markers. However, it is possible that there exists an expression threshold of intracellular neural stem cell
expression that aligns more appropriately with surface marker–defined states.
Mass cytometry used to study GSC biology. This work demonstrates the utility of mass cytometry
to characterize GSC signaling at the single-cell level in fresh specimens and longer term cultures.
A point worth noting is that GSCs derived from patient 4 and placed in short-term culture differed
substantially from the GSCs present at diagnosis, in terms of signaling and enrichment of cell states
with high expression of CD133. Although this is but one example, these observations demonstrate
that GSC identity may drift while in culture; this corroborates a bulk RNA-Seq study demonstrating
GSCs in culture develop distinct gene expression and epigenetic profiles from their parental tumors
(32). These differences may represent the selective pressures of standard media, particularly with
its high concentrations of growth factors, glucose, and glutamine. It is worth considering this as we
develop GSC-targeting therapies based largely on work in tissue culture or using cells from culture
engrafted into mice. Our observation that several GSC subpopulations were present in culture that
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Figure 9. The quadruple-high subpopulation has increased in vivo tumorigenicity. 500 cells of each indicated GSC
subpopulation of MGG8 were implanted in NCG mice (n = 6). Log-rank test was used to assess the significance of differences between each GSC subpopulation; *P < 0.05 vs quadruple-high cells. GSC, glioblastoma stem cell.

were not observed initially ex vivo may mean they either were present initially but below limits of
detection or reflect that the GSC states, as defined by surface markers, are fluid.
Larger antibody panels and greater sample sizes will provide a clearer understanding of GSC heterogeneity. For example, GSC subpopulations may vary at the single-cell level, in their degree of expression
of commonly amplified or mutated receptors, such as EGFR and PDGFRα. Understanding oncoprotein
expression at the single-cell level will inform our interpretation of the failures of targeted therapies in
patients with brain tumors. Additionally, including antibodies specific to oncoproteins, such as EGFRvIII
or IDH1R132H, will assist in differentiating tumor cells compared with nontransformed cells in the microenvironment. Finally, we expect that broader mass cytometry antibody panels will identify heterogeneous
expression of intracellular stem cell and precursor marker expression beyond those we present here, for
example, oligodendrocyte transcription factor 2 (71–73).
Our focus here has been on the subpopulation of cells within the tumor that express at least one surface marker associated with the GSC state. Moving forward, mass cytometry antibody panels for GBM
that combine assessment of GSCs, other GBM cells, and cells that compose the tumor microenvironment
will help refine appropriate targets for therapy (74, 75). For instance, mass cytometry was recently used
to characterize leukocyte landscapes in the environments of primary and metastatic brain tumors (76).
We envision an integrated approach to diagnostics and therapeutic development that includes assessing
single-cell proteomic signaling with RNA and DNA sequencing. By applying these analytics to highly treatment-resistant cells like GSCs, we will better understand the heterogeneous complexity of GBM and how
to best target these cells with precision.

Methods
Cell lines. GBM cancer stem cell line 0308 was provided by Howard Fine (Department of Neurology,
Weill Cornell Medicine, New York, New York, USA) (37, 77). TS667 from a patient with primary GBM
was derived in-house (78), as was MGG8 from a patient with primary GBM (79). 0308 and TS667
cells were cultured in Neurobasal media (Life Technologies) supplemented with 0.5× B27 without vitamin A (Thermo Fisher), 0.5× N2 supplement (Thermo Fischer), 2 mM L-glutamine (Thermo Fisher), 1
mM sodium pyruvate (Thermo Fisher), 50 μg/ml EGF (Peprotec), and 50 μg/ml basic FGF (Peprotec).
MGG8 cells were cultured in Neurobasal media (Life Technologies) supplemented with 1× B27 without
vitamin A, 1× N2 supplement, 3 mM GlutaMAX (Gibco), 5 mg/ml heparin (Stem Cell Technologies),
20 ng/ml EGF (Peprotec), and 20 μg/ml basic FGF (Peprotec).
Flow cytometry analysis and clonogenic assay. 106 cells were stained with CD133-APC (4 μl/106 cells,
TMP4, Invitrogen), CD44-Alexa Fluor 700 (2 μl/106 cells, BJ18, Biolegend), CD15-FITC (2 μl/106
cells, HI98, Biolegend), and α6 integrin-Brilliant Violet 421 (2 μl/106 cells, GoH3, Biolegend) for 15
minutes on ice. Fluorescence-minus-one controls were used. Positive and negative populations were
gated according to Supplemental Figure 3. All cell analyses and sorting were performed on a FACS
Aria II (BD Biosciences). For the clonogenic assay, we plated 120, 24, 5, and 1 cells per well; 12–18
replicates per dilution in ultralow attachment surface plates. Clonogenic cell frequency was analyzed
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using ELDA (http://bioinf.wehi.edu.au/software/elda/) (39). GSC subpopulation clonogenic frequencies were analyzed with 1-way ANOVA with Tukey’s post hoc test.
Cell viability. Five hundred cells of each GSC subpopulation studied were plated in 96-well plates in
triplicates. Cells were treated with increasing concentrations of XAV939 (0.03, 0.1, 0.3, 1, 3, 10, 50 μM;
Selleckchem, catalog S1180). Cell viability was measured using CellTiter-Glo (Promega, catalog G7572)
after 5 days incubation at 37oC. All data were normalized to day 0 and expressed as a relative cell number.
Patient samples. Fresh GBM specimens were obtained from freshly resected, excess surgical material
from patients at Barnes-Jewish Hospital.
Tumor dissociation. Fresh tumor samples were dissociated using Brain Tumor Dissociation Kit (Miltenyi
Biotec, catalog 130-095-942) followed by treatment with Myelin Removal Beads II (Miltenyi Biotec, catalog 130-096-733) and Debris Removal Solution (Miltenyi, catalog 130-109-38), according to manufacturer’s
instruction. Cells were counted and immediately labeled for mass cytometry analysis.
Mass cytometry staining and analysis. 3 × 106 cells from GSC lines or from patient samples were stained
for mass cytometry as described previously (80) using a panel of 20 antibodies (Table 1) and cisplatin to
identify dead cells (81). GSCs were differentiated with 10% FBS in DMEM for 6 weeks as negative controls
for cell-surface markers. These cells were run alongside the GSCs. Individual sample read-outs were recorded on a CyTOF2 mass cytometer (Fluidigm). At least 2.5 × 105 events were recorded for each sample and
uploaded to Cytobank (http://cytobank.org) (82) for subsequent analysis.
Mice and tumor implantation. Human GBM cells (MGG8) were grown in Neurobasal media with supplements as described above. Cells were harvested and dissociated with Accumax (Innovative Cell Technologies) then washed and resuspended in fresh media. GSC subpopulations expressing a single GSC cell-surface marker were enriched using LD columns (Miltenyi Biotec), according to manufacturer’s instruction.
For each GSC subpopulation, 30 × 106 cells were incubated with stem cell surface antibody minus the
corresponding highly expressed marker. GSCs were incubated on ice for 15 minutes with CD133-APC (4
μl/106 cells, TMP4, Invitrogen), CD44-Alexa Fluor 700 (2 μl/106 cells, BJ18, Biolegend), CD15-Brilliant
Violet 605 (2 μl/106 cells, HI98, Biolegend), and α6 integrin-Brilliant Violet 421 (2 μl/106 cells, GoH3,
Biolegend). After enrichment, GSCs were labeled with the corresponding missing antibody, sorted for the
single markers, and immediately implanted.
A total of 500 cells per animal were implanted into 6-week-old NCG female mice (NOD-Prkdcem26Cd52Ilem26Cd22
/NjuCrl; Charles River Laboratory). Briefly, animals were anesthetized by intraperitoneal injection
2rg
of ketamine (10 mg/kg) and placed in a stereotactic apparatus (Stoelting). An incision was made over the
cranial midline and a burr hole was made 1.5 mm anterior to the lambda and 2.5 mm right of the midline. A
29.5-gauge Hamilton syringe was inserted to a depth of 3 mm and withdrawn 0.5 mm to a depth of 2.5 mm.
MGG8 cells (3 μl) were injected over the course of 5 minutes. The incision site was closed by Vetbond (3M).
Animal monitoring. Mice were monitored for status daily and sacrificed when neurological deficits
became significant.
Statistics. All grouped data are presented as mean ± SEM as indicated. All statistical analyses were
performed using R version 3.5.0 (R Foundation for Statistical Computing) and the tidyverse library (R
package version 1.2.1). Supplemental analysis was performed using Prism 7.0 software (GraphPad).
ANOVA with Tukey’s post hoc test was used to assess the significance of differences between each GSC
subpopulation in clonogenic assay. Kruskal-Wallis with Mann-Whitney post hoc test was used to assess
the significance of non-phospho-β-catenin and pP65 between GSCs and cells with low expression of
surface markers. Kruskal-Wallis with Bonferroni’s post hoc tests were used to assess the significance of
differences between GSCs grouped by the number of highly expressed surface markers of non–phospho-β-catenin. For animal survival analysis, Kaplan-Meier curves were generated, and log-rank (Mantel-Cox) test was performed to assess difference relative to quadruple-high cells. A P value of less than
0.05 was considered significant.
Study approval. Approval for the use of human subject material after informed consent was granted
by the Institutional Review Board of Washington University School of Medicine in accordance with IRB
protocol 201111001. Animal studies were performed in accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals (National Academies Press, 2011). The protocols were approved
by the Institutional Animal Care and Use Committee at the Washington University School of Medicine
(assurance no. A338101). Inoculations were performed under anesthesia induced and maintained with
ketamine hydrochloride and xylazine, and all efforts were made to minimize animal suffering.
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